News
ITCI
55.62
-2.75%
-1.57
Wasatch Global’s Strongest Q1 Contributor: Intra-Cellular Therapies (ITCI)
Wasatch Global Investors, an investment management firm, published its “Wasatch Ultra Growth Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. Growth stocks fared worse than value stocks in the quarter, with the benchmark R...
Insider Monkey · 5d ago
Intra-Cellular initiated Buy at UBS on rollout of depression medication
Intra-Cellular Therapies (NASDAQ:ITCI) closed higher on Tuesday after UBS launched its coverage with a Buy rating and a $75 per share target, noting that the commercial-stage pharma company is set
Seekingalpha · 06/14 20:01
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022
Upgrades
Benzinga · 06/14 14:03
UBS Initiates Coverage on Intra-Cellular Therapies With Buy Rating, $75 Price Target
MT Newswires · 06/14 11:54
Intra-Cellular Therapies Highlights Lumateperone Bipolar Depression Data Presentations At 2022 International Society For Bipolar Disorders Experience
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced data presentations at
Benzinga · 06/13 12:10
Intra-Cellular Therapies Highlights Lumateperone Bipolar Depression Data Presentations at the 2022 International Society for Bipolar Disorders (ISBD) Experience
NEW YORK, June 13, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced data present...
GlobeNewswire · 06/13 12:00
Looking Into Intra-Cellular Therapies's Return On Capital Employed
According to Benzinga Pro data, during Q1, Intra-Cellular Therapies (NASDAQ:ITCI) posted sales of $35.00 million. Earnings were up 15.88%, but Intra-Cellular Therapies still reported an overall loss of $72.12 million.
Benzinga · 06/09 14:12
Those who invested in Intra-Cellular Therapies (NASDAQ:ITCI) five years ago are up 457%
Buying shares in the best businesses can build meaningful wealth for you and your family. And we've seen some truly...
Simply Wall St. · 05/29 12:38
Intra-Cellular Therapies Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating
Intra-Cellular Therapies shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Investor's Business Daily · 05/11 19:55
Robust Uptake Of Antipsychotic Drug Boosts Intra-Cellular's Q1 Earnings
Benzinga · 05/10 18:49
Intra-Cellular rises 18% as robust demand for bipolar depression drug drives Q1 beat
Intra-Cellular Therapies (NASDAQ:ITCI +18.1%) is trading higher after the company posted better-than-expected Q1 revenue, helped by robust demand for its bipolar depression drug, Caplyta. Net product revenues of Caplyta rose 123%
Seekingalpha · 05/10 17:12
Sector Update: Health Care Stocks Carried Higher by Surging Biotechs
MT Newswires · 05/10 16:02
77 Stocks Moving In Tuesday's Mid-Day Session
Gainers
Benzinga · 05/10 16:01
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/10 13:23
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 16.13% and 5.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/10 12:45
Update: Intra-Cellular Therapies Q1 Loss Expands; Revenue Rises; Shares Rise Tuesday Afternoon
MT Newswires · 05/10 12:27
Recap: Intra-Cellular Therapies Q1 Earnings
  Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/10 12:03
Intra-Cellular Therapies Q1 EPS $(0.78) Beats $(0.92) Estimate, Sales $35.00M Beat $33.65M Estimate
Intra-Cellular Therapies (NASDAQ:ITCI) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(0.92) by 15.22 percent. This is a 20 percent decrease over losses of $(0.65) per share
Benzinga · 05/10 11:56
Intra-Cellular Therapies GAAP EPS of -$0.78 beats by $0.15, revenue of $35M beats by $1.48M
Intra-Cellular Therapies press release (NASDAQ:ITCI): Q1 GAAP EPS of -$0.78 beats by $0.15. Revenue of $35M (+120.1% Y/Y) beats by $1.48M.
Seekingalpha · 05/10 11:36
Intra-Cellular Therapies Q1 Loss Expands; Revenue Rises
MT Newswires · 05/10 09:23
More
Webull provides a variety of real-time ITCI stock news. You can receive the latest news about Intra Cellular through multiple platforms. This information may help you make smarter investment decisions.
About ITCI
Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused on the discovery, clinical development and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company provides CAPLYTA (lumateperone) for the treatment of schizophrenia in adults. The CAPLYTA is a prescription medicine used to treat the depressive episodes in adults with bipolar I or II, that can be taken alone or with lithium or valproate. The Company's pipeline is focused on three platforms: lumateperone and follow-on compounds, a phosphodiesterase 1 (PDE1) inhibitor platform and discovery platform which includes ITI-333 a novel compound with high affinity at serotonin 5-HT2A, dopamine D1 and mu opioid (MOP) receptors. The Company’s subsidiaries are ITI, Inc. (ITI) and ITI Limited.